{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:32:46Z","timestamp":1791055966251,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1038\/ncpneuro0376","type":"journal-article","created":{"date-parts":[[2007,1,5]],"date-time":"2007-01-05T11:21:17Z","timestamp":1167996077000},"page":"36-44","source":"Crossref","is-referenced-by-count":121,"title":["Drug Insight: the use of intravenous immunoglobulin in neurology\u2014therapeutic considerations and practical issues"],"prefix":"10.1038","volume":"3","author":[{"given":"Ralf","family":"Gold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinos C","family":"Dalakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncpneuro0376_CR1","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","volume":"317","author":"P Imbach","year":"1981","unstructured":"Imbach P  et al. (1981) High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 317: 1228\u20131231","journal-title":"Lancet"},{"key":"BFncpneuro0376_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S1474-4422(03)00264-3","volume":"2","author":"R Gold","year":"2003","unstructured":"Gold R  et al. (2003) Immunotherapy in autoimmune neuromuscular disorders. Lancet Neurol 2: 22\u201332","journal-title":"Lancet Neurol"},{"key":"BFncpneuro0376_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nri821","volume":"2","author":"EM Shevach","year":"2002","unstructured":"Shevach EM (2002) CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2: 389\u2013400","journal-title":"Nat Rev Immunol"},{"key":"BFncpneuro0376_CR4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1056\/NEJMra993360","volume":"345","author":"MD Kazatchkine","year":"2001","unstructured":"Kazatchkine MD and Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345: 747\u2013755","journal-title":"N Engl J Med"},{"key":"BFncpneuro0376_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1385\/CRIAI:29:3:201","volume":"29","author":"N Misra","year":"2005","unstructured":"Misra N  et al. (2005) Intravenous immunoglobulin and dendritic cells. Clin Rev Allergy Immunol 29: 201\u2013205","journal-title":"Clin Rev Allergy Immunol"},{"key":"BFncpneuro0376_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/ana.10205","volume":"51","author":"B Buchwald","year":"2002","unstructured":"Buchwald B  et al. (2002) Intravenous immunoglobulins neutralize blocking antibodies in Guillain\u2013Barr\u00e9 syndrome. Ann Neurol 51: 673\u2013680","journal-title":"Ann Neurol"},{"key":"BFncpneuro0376_CR7","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1093\/brain\/awg235","volume":"126","author":"BC Jacobs","year":"2003","unstructured":"Jacobs BC  et al. (2003) Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 126: 2220\u20132234","journal-title":"Brain"},{"key":"BFncpneuro0376_CR8","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/intimm\/dxf099","volume":"14","author":"Y Shoenfeld","year":"2002","unstructured":"Shoenfeld Y  et al. (2002) Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 14: 1303\u20131311","journal-title":"Int Immunol"},{"key":"BFncpneuro0376_CR9","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00115-004-1733-4","volume":"75","author":"M Stangel","year":"2004","unstructured":"Stangel M and Gold R (2004) Use of i.v. immunoglobulins in neurology: evidence-based consensus [German]. Nervenarzt 75: 801\u2013815","journal-title":"Nervenarzt"},{"key":"BFncpneuro0376_CR10","first-page":"4","volume":"12","author":"M Stangel","year":"2005","unstructured":"Stangel M and Gold R (2005) Intravenous immunoglobulins in MS. Int MS J 12: 4\u201310","journal-title":"Int MS J"},{"key":"BFncpneuro0376_CR11","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00415-004-0495-z","volume":"251","author":"A Achiron","year":"2004","unstructured":"Achiron A  et al. (2004) Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 251: 1133\u20131137","journal-title":"J Neurol"},{"key":"BFncpneuro0376_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0140-6736(05)67102-4","volume":"366","author":"M Keegan","year":"2005","unstructured":"Keegan M  et al. (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366: 579\u2013582","journal-title":"Lancet"},{"key":"BFncpneuro0376_CR13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1191\/096120399678841007","volume":"8","author":"Y Levy","year":"1999","unstructured":"Levy Y  et al. (1999) A study of 20 SLE patients with intravenous immunoglobulin\u2014clinical and serologic response. Lupus 8: 705\u2013712","journal-title":"Lupus"},{"key":"BFncpneuro0376_CR14","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","volume":"326","author":"FG van der Meche","year":"1992","unstructured":"van der Meche FG and Schmitz PI (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain\u2013Barr\u00e9 syndrome. N Engl J Med 326: 1123\u20131129","journal-title":"N Engl J Med"},{"key":"BFncpneuro0376_CR15","doi-asserted-by":"crossref","unstructured":"Plasma Exchange\/Sandoglobulin Guillain\u2013Barr\u00e9 Syndrome Trial Group (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain\u2013Barr\u00e9 syndrome. Lancet 349: 225\u2013230","DOI":"10.1016\/S0140-6736(96)09095-2"},{"key":"BFncpneuro0376_CR16","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/brain\/118.4.841","volume":"118","author":"LH Visser","year":"1995","unstructured":"Visser LH  et al. (1995) Guillain\u2013Barr\u00e9 syndrome without sensory loss (acute motor neuropathy): a subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain\u2013Barr\u00e9 Study Group. Brain 118: 841\u2013847","journal-title":"Brain"},{"key":"BFncpneuro0376_CR17","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/ana.410440512","volume":"44","author":"RD Hadden","year":"1998","unstructured":"Hadden RD  et al. (1998) Electrophysiological classification of Guillain\u2013Barr\u00e9 syndrome: clinical associations and outcome. Plasma Exchange\/Sandoglobulin Guillain\u2013Barr\u00e9 Syndrome Trial Group. Ann Neurol 44: 780\u2013788","journal-title":"Ann Neurol"},{"key":"BFncpneuro0376_CR18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","volume":"363","author":"R van Koningsveld","year":"2004","unstructured":"van Koningsveld R  et al. (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain\u2013Barr\u00e9 syndrome: randomised trial. Lancet 363: 192\u2013196","journal-title":"Lancet"},{"key":"BFncpneuro0376_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1136\/jnnp.71.2.235","volume":"71","author":"JC Raphael","year":"2001","unstructured":"Raphael JC  et al. (2001) Intravenous immune globulins in patients with Guillain\u2013Barr\u00e9 syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 71: 235\u2013238","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFncpneuro0376_CR20","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/brain\/119.4.1067","volume":"119","author":"AF Hahn","year":"1996","unstructured":"Hahn AF  et al. (1996) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy\u2014a double-blind, placebo-controlled, cross-over study. Brain 119: 1067\u20131077","journal-title":"Brain"},{"key":"BFncpneuro0376_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ana.1088","volume":"50","author":"R Hughes","year":"2001","unstructured":"Hughes R  et al. (2001) Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50: 195\u2013201","journal-title":"Ann Neurol"},{"key":"BFncpneuro0376_CR22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1212\/WNL.56.4.445","volume":"56","author":"JR Mendell","year":"2001","unstructured":"Mendell JR  et al. (2001) Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56: 445\u2013449","journal-title":"Neurology"},{"key":"BFncpneuro0376_CR23","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/ana.410360607","volume":"36","author":"PJ Dyck","year":"1994","unstructured":"Dyck PJ  et al. (1994) A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36: 838\u2013845","journal-title":"Ann Neurol"},{"key":"BFncpneuro0376_CR24","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1212\/WNL.55.9.1256","volume":"55","author":"P Federico","year":"2000","unstructured":"Federico P  et al. (2000) Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 55: 1256\u20131262","journal-title":"Neurology"},{"key":"BFncpneuro0376_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/brain\/124.1.145","volume":"124","author":"JM Leger","year":"2001","unstructured":"Leger JM  et al. (2001) Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 124: 145\u2013153","journal-title":"Brain"},{"key":"BFncpneuro0376_CR26","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1136\/jnnp.59.3.248","volume":"59","author":"LH Van den Berg","year":"1995","unstructured":"Van den Berg LH  et al. (1995) Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 59: 248\u2013252","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFncpneuro0376_CR27","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1212\/01.WNL.0000110185.23464.A1","volume":"62","author":"F Terenghi","year":"2004","unstructured":"Terenghi F  et al. (2004) How long is IVIg effective in multifocal motor neuropathy? Neurology 62: 666\u2013668","journal-title":"Neurology"},{"key":"BFncpneuro0376_CR28","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1007\/s00415-002-0808-z","volume":"249","author":"G Comi","year":"2002","unstructured":"Comi G  et al. (2002) A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 249: 1370\u20131377","journal-title":"J Neurol"},{"key":"BFncpneuro0376_CR29","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/ana.410400516","volume":"40","author":"MC Dalakas","year":"1996","unstructured":"Dalakas MC  et al. (1996) A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 40: 792\u2013795","journal-title":"Ann Neurol"},{"key":"BFncpneuro0376_CR30","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/mus.10359","volume":"27","author":"S Renaud","year":"2003","unstructured":"Renaud S  et al. (2003) Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 27: 611\u2013615","journal-title":"Muscle Nerve"},{"key":"BFncpneuro0376_CR31","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ana.410410615","volume":"41","author":"P Gajdos","year":"1997","unstructured":"Gajdos P  et al. (1997) Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 41: 789\u2013796","journal-title":"Ann Neurol"},{"key":"BFncpneuro0376_CR32","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","volume":"62","author":"P Gajdos","year":"2005","unstructured":"Gajdos P  et al. (2005) Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin\u2014a randomized double-blind clinical trial. Arch Neurol 62: 1689\u20131693","journal-title":"Arch Neurol"},{"key":"BFncpneuro0376_CR33","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas MC  et al. (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329: 1993\u20132000","journal-title":"N Engl J Med"},{"key":"BFncpneuro0376_CR34","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1212\/WNL.48.3.712","volume":"48","author":"MC Dalakas","year":"1997","unstructured":"Dalakas MC  et al. (1997) Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 48: 712\u2013716","journal-title":"Neurology"},{"key":"BFncpneuro0376_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s004150050005","volume":"247","author":"M Walter","year":"2000","unstructured":"Walter M  et al. (2000) High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 247: 22\u201328","journal-title":"J Neurol"},{"key":"BFncpneuro0376_CR36","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/S0140-6736(05)66376-3","volume":"365","author":"C Sommer","year":"2005","unstructured":"Sommer C  et al. (2005) Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 365: 1406\u20131411","journal-title":"Lancet"},{"key":"BFncpneuro0376_CR37","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa01167","volume":"345","author":"MC Dalakas","year":"2001","unstructured":"Dalakas MC  et al. (2001) High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 345: 1870\u20131876","journal-title":"N Engl J Med"},{"key":"BFncpneuro0376_CR38","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1212\/WNL.57.5.801","volume":"57","author":"Y Du","year":"2001","unstructured":"Du Y  et al. (2001) Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 57: 801\u2013805","journal-title":"Neurology"},{"key":"BFncpneuro0376_CR39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/ana.10253","volume":"52","author":"R Dodel","year":"2002","unstructured":"Dodel R  et al. (2002) Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 52: 253\u2013256","journal-title":"Ann Neurol"},{"key":"BFncpneuro0376_CR40","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1136\/jnnp.2003.033399","volume":"75","author":"RC Dodel","year":"2004","unstructured":"Dodel RC  et al. (2004) Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 75: 1472\u20131474","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFncpneuro0376_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0022-510X(02)00316-7","volume":"205","author":"H Gonzalez","year":"2002","unstructured":"Gonzalez H  et al. (2002) Prior poliomyelitis\u2014evidence of cytokine production in the central nervous system. J Neurol Sci 205: 9\u201313","journal-title":"J Neurol Sci"},{"key":"BFncpneuro0376_CR42","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jneuroim.2004.01.010","volume":"150","author":"H Gonzalez","year":"2004","unstructured":"Gonzalez H  et al. (2004) Prior poliomyelitis\u2014IVIg treatment reduces proinflammatory cytokine production. J Neuroimmunol 150: 139\u2013144","journal-title":"J Neuroimmunol"},{"key":"BFncpneuro0376_CR43","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1474-4422(06)70447-1","volume":"5","author":"H Gonzalez","year":"2006","unstructured":"Gonzalez H  et al. (2006) Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial. Lancet Neurol 5: 493\u2013500","journal-title":"Lancet Neurol"},{"key":"BFncpneuro0376_CR44","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/ncpneuro0300","volume":"2","author":"JM Siegel","year":"2006","unstructured":"Siegel JM and Boehmer LN (2006) Narcolepsy and the hypocretin system\u2014where motion meets emotion. Nat Clin Pract Neurol 2: 548\u2013556","journal-title":"Nat Clin Pract Neurol"},{"key":"BFncpneuro0376_CR45","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/ana.20339","volume":"56","author":"Y Dauvilliers","year":"2004","unstructured":"Dauvilliers Y  et al. (2004) Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 56: 905\u2013908","journal-title":"Ann Neurol"},{"key":"BFncpneuro0376_CR46","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/ana.20892","volume":"60","author":"Y Dauvilliers","year":"2006","unstructured":"Dauvilliers Y (2006) Follow-up of four narcolepsy patients treated with intravenous immunoglobulins. Ann Neurol 60: 153","journal-title":"Ann Neurol"},{"key":"BFncpneuro0376_CR47","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s00415-003-1085-1","volume":"250","author":"M Stangel","year":"2003","unstructured":"Stangel M  et al. (2003) Side effects of intravenous immunoglobulins in neurological autoimmune disorders\u2014a prospective study. J Neurol 250: 818\u2013821","journal-title":"J Neurol"},{"key":"BFncpneuro0376_CR48","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B","volume":"22","author":"MC Dalakas","year":"1999","unstructured":"Dalakas MC (1999) Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 22: 1479\u20131497","journal-title":"Muscle Nerve"},{"key":"BFncpneuro0376_CR49","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/WNL.46.1.250","volume":"46","author":"R Voltz","year":"1996","unstructured":"Voltz R  et al. (1996) Reversible encephalopathy with cerebral vasospasm in a Guillain\u2013Barr\u00e9 syndrome patient treated with intravenous immunoglobulin. Neurology 46: 250\u2013251","journal-title":"Neurology"},{"issue":"Suppl 1","key":"BFncpneuro0376_CR50","first-page":"I\/58","volume":"249","author":"S Jarius","year":"2002","unstructured":"Jarius S (2002) Intravenous immunoglobulin preparations contain atypical antineutrophil antibodies and cause an oxidative burst in neutrophils. J Neurol 249 (Suppl 1): I\/58","journal-title":"J Neurol"},{"key":"BFncpneuro0376_CR51","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1191\/0961203303lu2168rr","volume":"14","author":"U Katz","year":"2005","unstructured":"Katz U and Schoenfeld Y (2005) Review: intravenous immunoglobulin therapy and thromboembolic complications. Lupus 14: 802\u2013808","journal-title":"Lupus"},{"key":"BFncpneuro0376_CR52","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1212\/01.WNL.0000068334.04500.08","volume":"60","author":"D Okuda","year":"2003","unstructured":"Okuda D  et al. (2003) Arterial thrombosis induced by IVIg and its treatment with tPA. Neurology 60: 1825\u20131826","journal-title":"Neurology"},{"key":"BFncpneuro0376_CR53","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1212\/01.WNL.0000068335.01620.9D","volume":"60","author":"JB Caress","year":"2003","unstructured":"Caress JB  et al. (2003) The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology 60: 1822\u20131824","journal-title":"Neurology"},{"key":"BFncpneuro0376_CR54","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","volume":"29","author":"H Orbach","year":"2005","unstructured":"Orbach H  et al. (2005) Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 29: 173\u2013184","journal-title":"Clin Rev Allergy Immunol"},{"key":"BFncpneuro0376_CR55","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1159\/000169055","volume":"16","author":"N Ahsan","year":"1996","unstructured":"Ahsan N  et al. (1996) Acute renal failure following immunoglobulin therapy. Am J Nephrol 16: 532\u2013536","journal-title":"Am J Nephrol"},{"key":"BFncpneuro0376_CR56","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1001\/archinte.154.17.1985","volume":"154","author":"N Ahsan","year":"1994","unstructured":"Ahsan N  et al. (1994) Intravenous immunoglobulin-induced osmotic nephrosis. Arch Int Med 154: 1985\u20131987","journal-title":"Arch Int Med"},{"key":"BFncpneuro0376_CR57","doi-asserted-by":"publisher","first-page":"721","DOI":"10.7326\/0003-4819-126-9-199705010-00008","volume":"126","author":"MC Dalakas","year":"1997","unstructured":"Dalakas MC (1997) Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 126: 721\u2013730","journal-title":"Ann Intern Med"},{"key":"BFncpneuro0376_CR58","first-page":"1","volume-title":"Immunoglobulins in Clinical Neurology","author":"PJ Spath","year":"2001","unstructured":"Spath PJ  et al. (2001) Production, tolerability and virus safety of intravenous immunoglobulins [German]. In Immunoglobulins in Clinical Neurology, 1\u201342 (Ed Berlit P) Darmstadt: Steinkopff Verlag"},{"key":"BFncpneuro0376_CR59","unstructured":"Dalakas MC: Practical guidelines in the administration of IVIg in neurological diseases. J Neurol Sci, in press"},{"key":"BFncpneuro0376_CR60","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1046\/j.1351-5101.2003.00701.x","volume":"10","author":"P McCrone","year":"2003","unstructured":"McCrone P  et al. (2003) Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 10: 687\u2013694","journal-title":"Eur J Neurol"},{"key":"BFncpneuro0376_CR61","doi-asserted-by":"publisher","first-page":"156","DOI":"10.2309\/155288504774654865","volume":"9","author":"M Hanchett","year":"2004","unstructured":"Hanchett M  et al. (2004) Current issues in immunoglobulin therapies. J Assoc Vasc Access 9: 156\u2013158","journal-title":"J Assoc Vasc Access"},{"key":"BFncpneuro0376_CR62","unstructured":"Reid B (online 22 August 2005) IVIG shortage driving patients to hospitals [\n                    http:\/\/www.drugtopics.com\/drugtopics\/article\/articleDetail.jsp?id=175684&searchString=ivig%20shortage\n                    \n                  ] (accessed 19 October 2006)"}],"container-title":["Nature Clinical Practice Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpneuro0376","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneuro0376.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneuro0376.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:28:30Z","timestamp":1684441710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpneuro0376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["BFncpneuro0376"],"URL":"https:\/\/doi.org\/10.1038\/ncpneuro0376","relation":{},"ISSN":["1745-834X","1745-8358"],"issn-type":[{"value":"1745-834X","type":"print"},{"value":"1745-8358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}